Sleep apnoea syndrome prevalence in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis
Clinical Kidney Journal · 04.01.2024 · 17 (1)
DOI: 10.1093/ckj/sfad179 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Kidney Journal, online erschienen am 14.11.2023. Verfasst von Anna Pisano und 4 weiteren Autor:innen. Beteiligte Einrichtung: CNR-Institute of Clinical Physiology; Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Several studies have examined the frequency of sleep apnoea (SA) in patients with chronic kidney disease (CKD), reporting different prevalence rates. Our systematic review and meta-analysis aimed to define the clinical penetrance of SA in CKD and end-stage kidney disease (ESKD) patients.
Methods
Ovid-MEDLINE and PubMed databases were explored up to 5 June 2023 to identify studies providing SA prevalence in CKD and ESKD patients assessed by different diagnostic methods, either sleep questionnaires or respiration monitoring equipment [such as polysomnography (PSG), type III portable monitors or other diagnostic tools]. Single-study data were pooled using the random-effects model. The Chi2 and Cochrane-I2 tests were used to assess the presence of heterogeneity, which was explored performing sensitivity and/or subgroup analyses.
Results
A cumulative analysis from 32 single-study data revealed a prevalence of SA of 57% [95% confidence interval (CI) 42%–71%] in the CKD population, whereas a prevalence of 49% (95% CI 47%–52%) was found pooling data from 91 studies in ESKD individuals. The prevalence of SA using instrumental sleep monitoring devices, including classical PSG and type III portable sleep monitors, was 62% (95% CI 52%–72%) and 56% (95% CI 42%–69%) in CKD and ESKD populations, respectively. Sleep questionnaires revealed a prevalence of 33% (95% CI 16%–49%) and 39% (95% CI 30%–49%).
Conclusions
SA is commonly seen in both non-dialysis CKD and ESKD patients. Sleep-related questionnaires underestimated the presence of SA in this population. This emphasizes the need to use objective diagnostic tools to identify such a syndrome in kidney disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CNR-Institute of Clinical Physiology; Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy.
- Renal Research Institute, NY, USA.
- Institute of Molecular Biology and Genetics (BIOGEM), Ariano Irpino, Italy.
- Associazione Ipertensione Nefrologia e Trapianto Renale (IPNET), Reggio Calabria, Italy.
- Department of Surgical and Medical Sciences-Magna Graecia, University of Catanzaro, Catanzaro, Italy.
- Nephology and Transplantation Unit, Grande Ospedale Metropolitano, Reggio Calabria, Italy.
ORCID-Profile: Carmine Zoccali, Davide Bolignano
Zitieren
APA
Pisano, A., Zoccali, C., Bolignano, D., D'Arrigo, G., & Mallamaci, F. (2024). Sleep apnoea syndrome prevalence in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Clinical Kidney Journal, 17(1). https://doi.org/10.1093/ckj/sfad179
Vancouver
Pisano A, Zoccali C, Bolignano D, D'Arrigo G, Mallamaci F. Sleep apnoea syndrome prevalence in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Clinical Kidney Journal. 2024;17(1). doi:10.1093/ckj/sfad179
BibTeX
@article{Pisano2024,
author = {Pisano, Anna and Zoccali, Carmine and Bolignano, Davide and D'Arrigo, Graziella and Mallamaci, Francesca},
title = {Sleep apnoea syndrome prevalence in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis},
journal = {Clinical Kidney Journal},
year = {2024},
volume = {17},
number = {1},
doi = {10.1093/ckj/sfad179}
}
EUVIMED